Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06805461Recruiting

PumaRx Registry Trial

Role: lead

NCT03257033Phase 3Recruiting

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Role: lead

NCT02591082Completed

Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter

Role: lead

NCT02237157Phase 1Completed

A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer

Role: lead

All 4 trials loaded